Synlogic (SYBX) Receives New Coverage from Analysts at Piper Jaffray Companies

Analysts at Piper Jaffray Companies assumed coverage on shares of Synlogic (NASDAQ:SYBX) in a research report issued on Monday, reports. The brokerage set an “overweight” rating and a $16.00 price target on the biotechnology company’s stock. Piper Jaffray Companies’ price objective suggests a potential upside of 65.63% from the stock’s current price.

A number of other research analysts have also recently weighed in on the stock. Wedbush initiated coverage on shares of Synlogic in a research note on Monday, November 27th. They issued an “outperform” rating and a $20.00 target price on the stock. Zacks Investment Research cut shares of Synlogic from a “hold” rating to a “sell” rating in a research note on Wednesday, November 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $18.75.

Synlogic (NASDAQ SYBX) traded up $0.01 during trading on Monday, reaching $9.66. 527,483 shares of the company traded hands, compared to its average volume of 173,420. Synlogic has a 1-year low of $8.76 and a 1-year high of $23.00. The stock has a market capitalization of $157.15, a PE ratio of -1.04 and a beta of 3.17.

Synlogic (NASDAQ:SYBX) last released its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($1.16). equities research analysts predict that Synlogic will post -5.42 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at

About Synlogic

Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with's FREE daily email newsletter.

Leave a Reply